What are you searching for?

Sign in
Breaking News, Promotions & Moves

Atara Appoints New R&D Head

Dietmar P. Berger, M.D., Ph.D. was most recently a senior vice president at Genentech

Atara Biotherapeutics has announced that Dietmar P. Berger, M.D., Ph.D. will join the company as global head of Research and Development.

 
“Dietmar is an accomplished physician-scientist and biotech research and development leader,” said Isaac Ciechanover, M.D., chief executive officer and president of Atara Biotherapeutics. “His deep experience building high-performing teams and strategic leadership of cancer immunotherapy development will help us shape the future of our innovative T-cell immunotherapy pipeline and technology platform.”
 
Prior to joining Atara, Dr. Berger was senior vice president and global head, Product Development, Clinical Science Hematology and Oncology at Roche/Genentech. In this role, he led medical strategy for the company’s global clinical development portfolio for cancer medicines, including global filings and approvals of Gazyva®, Cotellic®, Alecensa®, Tecentriq® and Hemlibra®. 
 
“I am excited to join Atara and lead research and development during this transformational period, including the ongoing Phase 3 development of tab-cel™, the potential first commercially available off-the-shelf, allogeneic T-cell immunotherapy,” said Dr. Berger. “Together with Atara’s strong R&D leadership team, we will continue to focus on rigorous late-stage clinical development and leveraging the full potential of our technology platform.”
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics